NasdaqGS:NUVLBiotechs
Nuvalent (NUVL) Valuation Check As FDA Accepts NDAs For Two Lung Cancer Therapies
Nuvalent (NUVL) is back in focus after the FDA accepted New Drug Applications for two of its targeted cancer drug candidates, zidesamtinib and neladalkib, following supportive clinical trial data in advanced lung cancer.
See our latest analysis for Nuvalent.
Despite a 31.55% total shareholder return over the past year and a very large 159.12% total shareholder return over three years, Nuvalent’s recent share price momentum has cooled. The 7 day share price return is 7.17%, and the year to...